Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET. The company said the presentation will be webcast live and available for replay for a limited time.
Investors can find the webcast link on the Edgewise Events & Presentations page and are advised to connect several minutes early to ensure a timely connection.
Positive
- None.
Negative
- None.
News Market Reaction – EWTX
In the Mar 4 session, EWTX gained 0.24%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Scientific conference | Neutral | -3.0% | Planned MDA data presentations on sevasemten and related Becker MD analyses. |
| Mar 02 | Inducement grants | Neutral | -2.4% | Inducement options for new employees under 2024 equity incentive plan. |
| Feb 26 | Earnings update | Neutral | -1.5% | Q4 and 2025 results with cash position and upcoming clinical catalysts. |
| Feb 05 | Investor conference | Neutral | -4.5% | Guggenheim biotech summit presentation with webcast access details. |
| Feb 02 | Inducement grants | Neutral | +2.6% | Stock option grants to new employees under Nasdaq inducement rules. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent announcements, including conferences, inducement grants and earnings, have generally been followed by modest price moves without a clear directional pattern.
Over the past months, Edgewise reported Q4 and full-year 2025 results with $530.1M in cash and highlighted multiple late-stage programs, while also issuing routine inducement option grants and announcing several investor and scientific conference presentations. Despite these updates, 24-hour reactions around prior news skewed slightly negative. Today’s Leerink conference appearance fits the ongoing pattern of active investor and scientific outreach rather than a discrete pipeline or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.html
SOURCE Edgewise Therapeutics